Ítem
Acceso Abierto
Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy
Título de la revista
Autores
Martínez-Micolta, Paula
Lemus, Hernan Nicolás
Archivos
Fecha
2016-01-19
Directores
Mayor, Luis Carlos
ISSN de la revista
Título del volumen
Editor
Universidad del Rosario
Buscar en:
Métricas alternativas
Resumen
Abstract
Objective: Epilepsy is a common neurologic disorder affecting 1% of the world population with one-third of these patients failing to have seizure control for more than one year. Clobazam is a long-acting benzodiazepine used worldwide for the treatment of epilepsy. This antiepileptic drug has demonstrated great clinical benefits with mild side effects. The objective of this study was to better understand the efficacy of clobazam treatment on adult patients with refractory epilepsy.
Design: A retrospective review of 44 adult patients with diagnosis of epilepsy that were seen at our Epilepsy Clinic between January 2014 and May 2015.
Setting: An outpatient epilepsy clinic at the Hospital Universitario Fundación Santa Fe de Bogota, Colombia.
Participants: 44 adult patients with diagnosis of epilepsy.
Measurements: Seizure frequency, adverse effects and the use of concomitant AEDs were reviewed in each of the patient´s clinical charts.
Results: The responder rate of patients with clobazam was 52% at 3 months, 50% at 6 months and 55% at 12 month. Seizure freedom rates at 3, 6 and 12 months were 18%, 25% and 25% respectively. Clobazam related adverse events occurred only in four patients (9%) at the end of the twelve months with somnolence being the most common.
Conclusion: These findings suggest that clobazam treatment in adult patients with focal or generalized epilepsy is effective and safe. Its use should be considered early when first-line agents fail to provide seizure control.
Palabras clave
add-on treatment , epilepsy , antiepileptic drugs , Clobazam
